PALO ALTO, CA / ACCESSWIRE / December 27, 2024 / 180 Life Sciences Corp. ("180" or the "Company") (NASDAQATNF), a biotechnology company that is currently refocusing its business on the international entertainment and iGaming sector, today announced that it has entered into a securities purchase agreement with several institutional investors to sell 1,200,000 shares of common stock in a registered direct offering priced at market under Nasdaq rules. In a concurrent private placement, the Company also agreed to issue unregistered warrants to purchase up to an aggregate of 1,200,000 shares of common stock. The combined effective offering price for each share of common stock and accompanying warrants is $2.41. The warrants will have an exercise price of $2.28 per share, will be exercisable immediately, and expire on the five and a half year anniversary from the date of issuance.

PALO ALTO, CA / ACCESSWIRE / December 12, 2024 / 180 Life Sciences Corp. ("180" or the "Company") is pleased to announce that it has regained compliance with Nasdaq Listing Rule 5605(c)(2), which requires Nasdaq listed companies to maintain an audit committee consisting of three independent directors. This development follows the recent appointment of Mr. Stephen Shoemaker as an independent director of the Company and as a member of the Company's audit committee. With this appointment, 180 is now in full compliance with all Nasdaq continued listing requirements and has remedied all previously announced deficiencies.

Announcing Acquisition of Advanced Gaming Technology Platform, Positive Progress on Legacy CBD Formulation, and Strengthened Balance Sheet

PALO ALTO, CA / ACCESSWIRE / December 4, 2024 / 180 Life Sciences Corp. ("180" or the "Company") (NASDAQATNF), a biotechnology company that is currently refocusing its business on the international entertainment and iGaming sector, today announced the appointment of Stephen Shoemaker to its Board of Directors, effective December 3, 2024.

PALO ALTO, CA / ACCESSWIRE / October 31, 2024 / 180 Life Sciences Corp. ("180" or the "Company") (NASDAQATNF) today announced the retention of Mr. Vaclav Vincalek as Senior Technology Consultant. An accomplished technologist with a strong record in technical leadership and strategy, Mr. Vincalek has guided numerous software businesses in areas of team development, technology systems architecture, and stakeholder communication.

PALO ALTO, CA / ACCESSWIRE / October 29, 2024 / 180 Life Sciences Corp. ("180" or the "Company") (NASDAQATNF) today announced the appointment of Mr. Jay Goodman to its Board of Directors, effective immediately. Mr. Goodman brings over a decade of expertise in the software-as-a-service (SaaS) and iGaming industries, along with more than seven years of experience in executive leadership roles. Mr. Goodman's distinguished career includes contributions to several high-growth companies, successful IPOs, and extensive work in the Asia Pacific and Japan markets.

PALO ALTO, CA / ACCESSWIRE / October 16, 2024 / 180 Life Sciences Corp. (NASDAQATNF)("180" or the "Company"), today released the following letter to stockholders from its Interim Chief Executive Officer, Blair Jordan.

180 Life Sciences (NASDAQATNF) today announced that it can now fully focus on developing its new iGaming business after officially regaining compliance with Nasdaq Listing Rule 5550(b)(1) on minimum stockholders’ equity. The company announced earlier this month that it will be strategically shifting towards the growing global iGaming sector as it seeks to leverage significant opportunities and establish itself as a key player in this market. 180 recently acquired a gaming platform that integrates the latest blockchain technology, thus promising transparency, security, and trust. The platform, expected to launch during Q1 2025, will accept cryptocurrency and fiat currency. The company will also continue to advance its legacy biotechnology business.

PALO ALTO, CA / ACCESSWIRE / October 9, 2024 / 180 Life Sciences Corp. (NASDAQATNF) (the "Company" or "180"), is pleased to announce that it has received confirmation from Nasdaq that the Company has officially regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires a minimum stockholders' equity of $2,500,000. With this important achievement, the Company can now fully focus on developing its newly announced iGaming business, while also continuing to advance its legacy biotechnology programs.

180 Life Sciences (NASDAQATNF), a clinical-stage biotechnology company, has released an update on several key initiatives, including announcing the acquisition of an advanced Gaming Technology Platform, positive progress on its Legacy CBD formulation and a strengthened balance sheet. According to the update, the company is shifting its focus as it enters the global iGaming market through its acquisition of a comprehensive intellectual property package, consisting of a complete back-end technology solution for online casino operations. In addition, the company anticipates retaining its current portfolio of biotechnology intellectual property as it reports positive study results exhibiting faster absorption and improved bioavailability for its new CBD pill formulation. 180 also noted that it expects to meet NASDAQ’s continued listing requirement, which requires maintenance of stockholders’ equity of at least $2.5 million; the company is also enhancing its financial position by settling meaningful legacy liabilities at substantial discounts and resolving certain legacy litigation matters

180 Life Sciences (NASDAQATNF) announced on Thursday its appointment of Omar Jimenez as its new Chief Financial Officer, effective September 30, 2024. Jimenez, a current director of the Company, will leverage his extensive financial management experience to steer the Company’s growth and innovation in the pharmaceutical and biotechnology sectors. With a background that includes leadership roles in companies like Golden Matrix Group and Alfadan, Inc., Jimenez brings a wealth of expertise in financial reporting, management, and capital markets. He holds a BBA in Accounting and Finance from the University of Miami and an MBA in Finance & Management from Florida International University. The Company expressed gratitude to outgoing CFO Ozan Pamir for his contributions.

PALO ALTO, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (“180” or the “Company”) is pleased to announce the appointment of Omar Jimenez as its new Chief Financial Officer, effective September 30, 2024. Mr. Jimenez, already a director of the Company, will play a key role in driving the financial strategy of the Company as it continues to grow and innovate in the pharma and biotechnology sectors.